Published in Science on November 24, 1989
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl Acad Sci U S A (1998) 2.20
Deciphering cellular states of innate tumor drug responses. Genome Biol (2006) 1.83
Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc Natl Acad Sci U S A (1993) 1.76
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology (2015) 1.42
Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol (1996) 1.37
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A (1991) 1.37
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm (2010) 1.17
Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. Antimicrob Agents Chemother (1992) 1.09
DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother (1992) 1.09
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer (1999) 1.09
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer (2011) 1.05
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer (1997) 0.98
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol (2013) 0.98
3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells. J Control Release (2012) 0.96
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer (1996) 0.95
Current perspectives on camptothecins in cancer treatment. Br J Cancer (1996) 0.90
Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med (2004) 0.90
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother (1999) 0.90
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One (2012) 0.89
The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells. J Virol (1991) 0.89
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol (2010) 0.88
Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer Suppl (1994) 0.85
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? Br J Cancer (1997) 0.85
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer (2000) 0.85
Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer (1992) 0.85
Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs (1999) 0.84
DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis (2012) 0.83
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer (1995) 0.82
Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis. Br J Pharmacol (2001) 0.82
Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice. J Control Release (2006) 0.80
Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target. Oncotarget (2012) 0.79
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer (1996) 0.79
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. Neoplasia (2004) 0.79
Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharm Res (2007) 0.79
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer (1998) 0.79
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem (2009) 0.79
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells. PLoS One (2015) 0.79
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs (1999) 0.79
Topoisomerase I inhibitors and drug resistance. Cytotechnology (1998) 0.78
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br J Cancer (2002) 0.78
Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromol Biosci (2009) 0.78
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs (2010) 0.78
Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Invest New Drugs (2000) 0.77
Alteration of Drug Sensitivity in Human Colon Cancer Cells after Exposure to Heat: Implications for Liver Metastasis Therapy using RFA and Chemotherapy. Int J Clin Exp Med (2008) 0.77
Synthesis of novel C5-curcuminoid-fatty acid conjugates and mechanistic investigation of their anticancer activity. Bioorg Med Chem Lett (2015) 0.77
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Invest New Drugs (2012) 0.77
Chemical conjugation of 2-hexadecynoic acid to C5-curcumin enhances its antibacterial activity against multi-drug resistant bacteria. Bioorg Med Chem Lett (2015) 0.77
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Invest New Drugs (2006) 0.77
Inhibition of retrovirus-induced disease in mice by camptothecin. J Virol (1993) 0.77
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Arthritis Res (2001) 0.76
ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther (2013) 0.76
Chemotherapy of Colorectal Cancer. Curr Treat Options Gastroenterol (1999) 0.75
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. Br J Cancer (1998) 0.75
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br J Cancer (1997) 0.75
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter. PLoS One (2017) 0.75
Expression of anionic glutathione S transferase (GST pi) gene in carcinomas of the uterine cervix and in normal cervices. Br J Cancer (1991) 0.75
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Invest New Drugs (2006) 0.75
Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Invest New Drugs (2001) 0.75
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem (1985) 8.60
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc (1971) 8.56
Transcription generates positively and negatively supercoiled domains in the template. Cell (1988) 5.73
Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol (1985) 5.00
Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA. Proc Natl Acad Sci U S A (1978) 4.54
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (1984) 4.52
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Purification and properties of bacteriophage T4-induced RNA ligase. Proc Natl Acad Sci U S A (1972) 4.18
Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res (1989) 4.01
Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem (1984) 3.98
Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci U S A (1981) 3.98
Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell (1980) 3.83
The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol (1988) 3.69
Interaction between DNA and Escherichia coli protein omega. Formation of a complex between single-stranded DNA and omega protein. J Biol Chem (1978) 3.35
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res (1988) 3.26
Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U S A (1987) 3.21
DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol (1994) 3.18
A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem (1981) 3.07
Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem (1983) 3.05
Transcription-driven supercoiling of DNA: direct biochemical evidence from in vitro studies. Cell (1989) 3.00
Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol (2001) 2.97
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A (1984) 2.84
T4 DNA topoisomerase: a new ATP-dependent enzyme essential for initiation of T4 bacteriophage DNA replication. Nature (1979) 2.76
The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 2.66
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
DNA-DNA gyrase complex: the wrapping of the DNA duplex outside the enzyme. Cell (1978) 2.60
Germination of Witchweed (Striga lutea Lour.): Isolation and Properties of a Potent Stimulant. Science (1966) 2.57
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res (1990) 2.49
Studies on ribonucleic acid ligase. Characterization of an adenosine triphosphate-inorganic pyrophosphate exchange reaction and demonstration of an enzyme-adenylate complex with T4 bacteriophage-induced enzyme. J Biol Chem (1974) 2.44
Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases. Nucleic Acids Res (1981) 2.39
Integration of the DNA of filamentous bacteriophage Cflt into the chromosomal DNA of its host. J Virol (1987) 2.31
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci U S A (1988) 2.29
Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A (1988) 2.26
On the degree of unwinding of the DNA helix by ethidium. II. Studies by electron microscopy. Biochim Biophys Acta (1975) 2.25
Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem (1996) 2.20
DNA topoisomerases--enzymes that catalyse the breaking and rejoining of DNA. CRC Crit Rev Biochem (1983) 2.20
Spontaneous regression of primary malignant melanomas with regional metastases. Cancer (1965) 2.15
Knotted single-stranded DNA rings: a novel topological isomer of circular single-stranded DNA formed by treatment with Escherichia coli omega protein. J Mol Biol (1976) 2.05
Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J Biol Chem (1985) 2.04
Macharistol, a new cytotoxic cinnamylphenol from the stems of Machaerium aristulatum. J Nat Prod (2001) 1.97
Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta (1989) 1.92
Overexpression of RNase H partially complements the growth defect of an Escherichia coli delta topA mutant: R-loop formation is a major problem in the absence of DNA topoisomerase I. Proc Natl Acad Sci U S A (1995) 1.89
Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem (1984) 1.88
Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res (1993) 1.88
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A (1985) 1.87
Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer (1977) 1.84
Patient transfers: medical practice as social triage. Am J Public Health (1984) 1.83
Recognition sites of eukaryotic DNA topoisomerase I: DNA nucleotide sequencing analysis of topo I cleavage sites on SV40 DNA. Nucleic Acids Res (1982) 1.78
Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J Natl Cancer Inst (1974) 1.74
Studies on the lymphocyte 5'-nucleotidase in chronic lymphocytic leukemia, infectious mononucleosis, normal subpopulations, and phytohemagglutinin-stimulated cells. Cancer Res (1974) 1.74
The effect of N acetyl C-galactosamine and other sugars on the mitogenic activity and attachment of PHA to tonsil cells. Blood (1968) 1.73
recA-independent and recA-dependent intramolecular plasmid recombination. Differential homology requirement and distance effect. J Mol Biol (1994) 1.72
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res (1989) 1.71
Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci U S A (1988) 1.70
Intra- and intermolecular strand transfer by HeLa DNA topoisomerase I. J Biol Chem (1982) 1.67
Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med (1999) 1.64
Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy. Cancer (1978) 1.64
Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res (2001) 1.63
Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res (1997) 1.63
Knotted DNA from bacteriophage capsids. Proc Natl Acad Sci U S A (1981) 1.59
In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin. Cell (1985) 1.57
Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem (1997) 1.56
Effect of tannins on screening of plant extracts for enzyme inhibitory activity and techniques for their removal. Phytomedicine (1996) 1.56
Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res (1985) 1.53
In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin. Mol Cell Biol (1986) 1.52
26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem (2001) 1.50
Expression of alpha-amylases, carbohydrate metabolism, and autophagy in cultured rice cells is coordinately regulated by sugar nutrient. Plant J (1994) 1.49
SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem (2000) 1.48
Metabolic derepression of alpha-amylase gene expression in suspension-cultured cells of rice. J Biol Chem (1991) 1.48
SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci U S A (2000) 1.47
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther (1983) 1.44
Studies on the regulation of one-carbon metabolism. II. Repression-derepression of serine hydroxymethyltransferase by methionine in Escherichia coli 113-3. J Biol Chem (1972) 1.42
The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res (1992) 1.42
Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res (1988) 1.41
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives. J Med Chem (1993) 1.41
Interaction between DNA and Escherichia coli DNA topoisomerase I. Formation of complexes between the protein and superhelical and nonsuperhelical duplex DNAs. J Biol Chem (1979) 1.41
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res (1989) 1.40
The role of vitamin E deficiency in the abnormal autohemolysis of acanthocytosis. Trans Assoc Am Physicians (1965) 1.39
Lymphocyte plasma membranes: analysis of proteins and glycoproteins by SDS-gel electrophoresis. Blood (1973) 1.38
DNA topoisomerases as anticancer drug targets. Adv Pharmacol (1990) 1.38
Phytohemagglutinin: inhibition of the agglutinating activity by N-acetyl-D-galactosamine. Science (1966) 1.34
Transplanted LDL and mannose-6-phosphate receptor internalization signals promote high-efficiency endocytosis of the transferrin receptor. EMBO J (1991) 1.34
Activity of delta8- and delta9-tetrahydrocannabinol and related compounds in the mouse. Science (1971) 1.34
p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood (1993) 1.34
DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res (1986) 1.33
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res (1989) 1.31
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31